Positive outcomes. Positive patient stories. These are our priorities at Paratek Pharmaceuticals. As a commercial-stage biopharmaceutical company, we develop transformative solutions for patients with infectious diseases and other difficult to treat conditions, and we believe that we have the right people, the right knowledge and the right drug to make a difference in patients’ lives.
Our Mission
To create positive stories for patients, physicians and caregivers based on trust and integrity. To accomplish this, our employees work hard to turn everyday decisions into everyday triumphs that advance our technology and strengthen Paratek.
Our Vision
To be a leading independent biopharmaceutical company providing novel life-saving products for life-threatening diseases or other public health threats.
Our Mission
To create positive stories for patients, physicians and caregivers based on trust and integrity. To accomplish this, our employees work hard to turn everyday decisions into everyday triumphs that advance our technology and strengthen Paratek.
Our Vision
To be a leading independent biopharmaceutical company providing novel life-saving products for life-threatening diseases or other public health threats.
Location: United States, Massachusetts, Boston
Employees: 51-200
Founded date: 1996
Investors 3
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Aisling Ca... | aislingcap... |
| - | InterWest ... | interwest.... |
Mentions in press and media 14
| Date | Title | Description |
| 03.08.2023 | Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million | - |
| 09.05.2023 | Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million | /EIN News/ -- -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022 -- Company Reiterates Full-Year Revenue Guidance of $143 to $158 Million -- Announce... |
| 09.05.2023 | Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million | - |
| 16.03.2023 | Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million | - |
| 05.01.2023 | Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract | - |
| 03.11.2022 | Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million | - |
| 03.08.2022 | Paratek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 Million | -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.1 Million from the Core Commercial Business, a 68% increase over Second Quarter 2021 -- Company Reiterates Full Year 2022 Financial Guidance BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) --... |
| 04.05.2022 | Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million | -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021 -- Omadacycline Demonstrated Potent In Vitro Efficacy Against Mycobacterium Avium Complex (MAC) in... |
| 14.03.2022 | Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million | -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $106.1 Million Comprised of $68.2 Million from the Core Commercial Business, a 76% increase over Prior Year, and $37.9 Million from the Initial Procurement of NUZYRA under the BARDA Bios... |
| 09.08.2021 | Paratek Pharmaceuticals : Announces Total Revenue of $57.5 Million in the Second Quarter 2021 | -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior Quarter -- Reported $37.9 Million in Revenue from the Delivery of the First BARDA Procurement of NUZYRA -- ... |
Show more